ALK and non-small cell lung carcinoma: Discovery of targetable driver oncogenes, particularly EGFR, ALK and ROS1, along with the development of immunotherapeutic agents, have opened up new treatment paradigms for NSCLC with treatment decisions now relying on biomarker assessment.